ADCT
Income statement / Annual
Last year (2024), ADC Therapeutics S.A.'s total revenue was $70.84 M,
an increase of 1.84% from the previous year.
In 2024, ADC Therapeutics S.A.'s net income was -$157.85 M.
See ADC Therapeutics S.A.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$70.84 M |
$69.56 M |
$209.91 M |
$33.92 M |
$0.00 |
$2.34 M |
$1.14 M |
$1.80 M |
| Cost of Revenue |
$5.95 M
|
$2.53 M
|
$3.30 M
|
$1.39 M
|
$141.82 M
|
$0.00
|
$118.09 M
|
$85.53 M
|
| Gross Profit |
$64.89 M
|
$67.03 M
|
$206.61 M
|
$32.52 M
|
-$141.82 M
|
$2.34 M
|
-$116.95 M
|
-$83.73 M
|
| Gross Profit Ratio |
0.92
|
0.96
|
0.98
|
0.96
|
0
|
1
|
-102.58
|
-46.44
|
| Research and Development Expenses |
$109.63 M
|
$127.13 M
|
$186.46 M
|
$158.00 M
|
$142.03 M
|
$107.54 M
|
$118.31 M
|
$85.53 M
|
| General & Administrative Expenses |
$64.47 M
|
$72.88 M
|
$107.74 M
|
$71.46 M
|
$55.13 M
|
$14.20 M
|
$8.60 M
|
$7.81 M
|
| Selling & Marketing Expenses |
$21.44 M
|
$33.01 M
|
$35.75 M
|
$64.78 M
|
$22.10 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$85.91 M
|
$105.89 M
|
$143.49 M
|
$136.24 M
|
$77.23 M
|
$14.20 M
|
$8.60 M
|
$7.81 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$141.82 M
|
$0.00
|
$166.00 K
|
$137.00 K
|
| Operating Expenses |
$195.54 M
|
$233.02 M
|
$329.95 M
|
$294.24 M
|
$77.45 M
|
$121.74 M
|
$127.08 M
|
$93.47 M
|
| Cost And Expenses |
$201.49 M
|
$235.54 M
|
$333.25 M
|
$295.64 M
|
$219.26 M
|
$121.74 M
|
$127.08 M
|
$93.47 M
|
| Interest Income |
$12.27 M
|
$10.54 M
|
$2.57 M
|
$66.00 K
|
$832.00 K
|
$2.25 M
|
$2.86 M
|
$1.03 M
|
| Interest Expense |
$50.21 M
|
$46.33 M
|
$36.73 M
|
$18.34 M
|
$4.93 M
|
$156.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.28 M
|
$3.27 M
|
$2.39 M
|
$2.63 M
|
$821.00 K
|
$1.65 M
|
$513.00 K
|
$341.00 K
|
| EBITDA |
-$102.65 M |
-$145.83 M |
-$107.70 M |
-$230.54 M |
-$218.23 M |
-$114.10 M |
-$122.36 M |
-$91.33 M |
| EBITDA Ratio |
-1.45
|
-2.1
|
-0.51
|
-6.8
|
0
|
-48.76
|
-107.33
|
-50.65
|
| Operating Income Ratio |
-1.84
|
-2.39
|
-0.59
|
-7.72
|
0
|
-51.03
|
-110.47
|
-50.84
|
| Total Other Income/Expenses Net |
-$27.03 M
|
-$34.96 M
|
-$33.56 M
|
$10.22 M
|
-$26.70 M
|
$3.50 M
|
$3.07 M
|
$1.86 M
|
| Income Before Tax |
-$157.68 M
|
-$200.95 M
|
-$156.90 M
|
-$251.51 M
|
-$245.96 M
|
-$115.90 M
|
-$122.87 M
|
-$89.81 M
|
| Income Before Tax Ratio |
-2.23
|
-2.89
|
-0.75
|
-7.42
|
0
|
-49.53
|
-107.78
|
-49.81
|
| Income Tax Expense |
$166.00 K
|
$39.11 M
|
$227.00 K
|
-$21.48 M
|
$327.00 K
|
$582.00 K
|
$224.00 K
|
$48.00 K
|
| Net Income |
-$157.85 M
|
-$240.05 M
|
-$157.13 M
|
-$230.03 M
|
-$246.29 M
|
-$116.48 M
|
-$123.10 M
|
-$89.86 M
|
| Net Income Ratio |
-2.23
|
-3.45
|
-0.75
|
-6.78
|
0
|
-49.78
|
-107.98
|
-49.84
|
| EPS |
-1.62 |
-2.94 |
-1.99 |
-3 |
-3.77 |
-1.74 |
-2.29 |
-1.53 |
| EPS Diluted |
-1.62 |
-2.94 |
-1.99 |
-3 |
-3.77 |
-1.74 |
-2.29 |
-1.53 |
| Weighted Average Shares Out |
$97.16 M
|
$81.71 M
|
$78.15 M
|
$76.75 M
|
$65.41 M
|
$66.87 M
|
$53.83 M
|
$58.85 M
|
| Weighted Average Shares Out Diluted |
$97.16 M
|
$81.71 M
|
$78.15 M
|
$76.75 M
|
$65.41 M
|
$66.87 M
|
$53.83 M
|
$58.85 M
|
| Link |
|
|
|
|
|
|
|
|
